General
Preferred name
VEMURAFENIB
Synonyms
PLX-4032 ()
PLX-4032, Ro-5185426, RG-7204, Zelboraf ()
PLX4032 ()
RO5185426 ()
RG7204 ()
R7204 ()
PLX 4032 ()
ZELBORAF ()
RG 7204 ()
RG-7204 ()
RO 5185426 ()
RO-51-85426 ()
RO-5185426 ()
Vemurafenib (PLX4032) ()
RG7204, RO5185426,PLX4032 ()
P&D ID
PD003414
CAS
918504-65-1
1029872-54-5
Tags
natural product
drug
available
Approved by
FDA
First approval
2011
Drug Status
approved
Drug indication
Melanoma
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Vemurafenib is a Type-2 kinase inhibitor and was first approved by the FDA in 2011. (GtoPdb)
INDICATION Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] ; Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
DESCRIPTION Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. (PKIDB)
DESCRIPTION inhibitor of BRAF (Informer Set)
DESCRIPTION Potent and selective inhibitor of CDK2, CDK5, CDK1 and CDK9 (Tocris Bioactive Compound Library)
Cell lines
13
Organisms
0
Compound Sets
33
AdooQ Bioactive Compound Library
A10739
Axon Medchem Screening Library
1624
Cayman Chemical Bioactives
10618
ChEMBL Approved Drugs
CHEMBL1229517
ChEMBL Drugs
CHEMBL1229517
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
5893
Concise Guide to Pharmacology 2019/20
5893
Concise Guide to Pharmacology 2021/22
5893
Concise Guide to Pharmacology 2023/24
5893
Drug Repurposing Hub
DrugBank
DB08881
DrugBank Approved Drugs
DB08881
DrugCentral
4185
DrugCentral Approved Drugs
4185
DrugMAP
DM62UG5
DrugMAP Approved Drugs
DM62UG5
EU-OPENSCREEN Bioactive Compound Library
EOS101599
Guide to Pharmacology
5893
Informer Set
649420
LINCS compound set
10068-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1229517
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1229517
MedChem Express Bioactive Compound Library
HY-12057
NCATS Inxight Approved Drugs
207SMY3FQT
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
PLX-4032
TargetMol Bioactive Compound Library
T2382
T8654
Tocris Bioactive Compound Library
7309
ZINC Tool Compounds
ZINC000052509366
External IDs
40
Properties
(calculated by RDKit )
Molecular Weight
489.07
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
4
cLogP
5.54
TPSA
91.92
Fraction CSP3
0.13
Chiral centers
0.0
Largest ring
6.0
QED
0.33
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
BRAF
Ack1
MAP4K5 (KHS1)
b-RAF
B-Raf (V600E)
c-Raf
SRMS
FGR
BRAF, RAF1
B-Raf inhibitor
Autophagy,Raf
Compound status
FDA
Pathway
Angiogenesis
MAPK
Tyrosine Kinase/Adaptors
Autophagy
MAPK/ERK Pathway
Primary Target
Raf Kinase
MOA
ACK
Raf
Tyrosine Kinases
Inhibitor
Inhibitors of Signal Transduction Pathways
Raf kinase B Inhibitors
Raf inhibitor
Member status
member
Indication
melanoma
Source data